BURLINGTON, Mass., Oct. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the HIV drug market will experience an average annual increase of 3.1 percent from 2009 to 2014 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Thereafter, market growth will slow to 2.2 percent annually from 2014 through 2019, owing largely to the generic erosion of several key antiretroviral agents.

The Pharmacor 2010 findings from the topic entitled Human Immunodeficiency Virus finds that although sales of Bristol-Myers Squibb/Gilead's Atripla will continue to increase over the next several years, two emerging fixed-dose combination products—Gilead's Quad and Tibotec/Gilead's rilpivirine/tenofovir/emtricitabine—will challenge Atripla's dominance in the HIV market though 2019. Specifically, Quad is forecast to be the top-selling agent for HIV, with sales of $2.8 billion in 2019.

"Assuming concerns over rilpivirine's virological failure rate are resolved, the coformulation of rilpivirine/tenofovir/emtricitabine has the potential to displace Atripla as the non-nucleoside reverse transcriptase inhibitor-based regimen of choice, due to its greatly improved safety profile," said Decision Resources Analyst Courtney Stanton, Ph.D. "Additionally, if Quad's impressive safety and efficacy data in Phase II clinical trials are confirmed in Phase III, Atripla will lose even greater market share once Quad hits the market."

The Pharmacor 2010 findings also reveal that the two most recently launched new drug classes—the integrase inhibitors and CCR5 antagonists—have received mixed reviews from interviewed HIV specialists. Merck's Isentress, the first-in-class integrase inhibitor, has been praised for its low-toxicity and high efficacy. However, physicians have also noted its comparatively low barrier to resistance, high cost and twice-daily dosing. Despite these concerns, the overall perception of Isentress is positive and the agent has seen a healthy uptake in the market, garnering more than eight percent patient share in 2009.

The sole CCR5 antagonist on the market, ViiV's Selzentry, has not had as positive a reception by prescribers. While Selzentry is recognized as a highly effective and safe treatment option, the major obstacles to its use have been the required tropism assay and limited patient eligibility.  

Additionally, an emerging focus on inflammation and aging in the more mature HIV population has prompted physician interest in therapeutic options that not only control viral replication, but also have additional therapeutic benefit, such as Tobira's TBR-652, a CCR5 inhibitor that has potential anti-inflammatory properties.

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Decision Resources, Inc.

Christopher Comfort



SOURCE Decision Resources, Inc.

Decision Resources' Forecast of Global Tanezumab Sales Slashed Following FDA Halt of Phase III Studies

View Now